A(MindMaze)ing DTx partnerships. Digital therapeutics (DTx) company MindMaze entered four new partnerships with Surgicorp, Alkholi, Guttmann Barcelona, and Swiss Rehabilitation. These agreements will help MindMaze expand its existing portfolio of DTx products to treat neurological conditions.
Maternal care partners. Maternal care provider Oula inked a partnership with Mount Sinai West to extend child-delivery hospital services to Oula’s patients. Looking forward, Oula plans to open its own birthing center in Manhattan.
RWE goes global. Real world evidence company Aetion secured a $110M Series C, led by Warburg Pincus. It plans to use the funds to expand its business in Europe and Asia. CB Insights clients can read more about real world evidence platforms here.
Microbes printing money. Ginkgo Bioworks — which calls itself “the organism company” — is going public via a SPAC that values it at $17.5B. Backed by Bill Gates, the company has built a number of partnerships across industries.
RNA for days. Moderna’s founder has launched another RNA company company — Laronde — with $50M in funding from Flagship Pioneering. The company will develop therapies with “endless RNA” that can increase the amount of protein produced by cells.
$1B for 37. Virtual clinical trials company Science 37 is going public via a SPAC that values it over $1B. The deal will provide the company with $250M in cash, which will be used to fuel continued growth.
Caris on my wayward son. Personalized medicine company Caris Life Sciences raised $830M in a financing that values it close to $8B. It will use the funds to continue developing a pan-cancer liquid biopsy test.
Let’s go on a trip. The first phase 3 trial with psychedelic-assisted therapy was just completed, with significant improvements for patients with severe PTSD. It may only be a matter of time before the FDA grants approval for psychoactive compounds to be used therapeutically.
83 pages on racial equity. The American Medical Association has vowed, in a new strategic plan, to dismantle racism in healthcare. The report has been criticized by some in the medical community as “lacking in targets, timelines, and teeth.”